ArticlePloS one2025
Insulin resistance markers HOMA-IR, TyG and TyG-BMI index in relation to heart failure risk: NHANES 2011-2016.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Association between triglyceride glucose index and risk of acute kidney injury in critically ill patients: a systematic review and meta-analysis.Frontiers in endocrinology · 2026Pooled it
- Elevated Endogenous Insulin and Insulin Resistance Are Associated With Progressive Diastolic Dysfunction and Worse Cardiovascular Outcomes.Circulation. Heart failure · 2026Article
- Biomarkers for Screening and Diagnosis of Heart Failure in Cardiovascular-Kidney-Metabolic Syndrome: A Narrative Review.International journal of molecular sciences · 2026Review
- Insulin Resistance Surrogates and Cognitive Impairment in Parkinson's Disease: A Cross-Sectional Study with Interpretable Machine Learning.Biomedicines · 2026Article
- HbA1c-to-HDL-C ratio and risk of incident cardiovascular disease among older adults: evidence from a 7-year prospective cohort study in southwestern China.Frontiers in public health · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundInsulin resistance (IR) is increasingly recognized as an important factor in the development of heart failure (HF). This study aimed to evaluate the association and predictive ability of three IR markers-HOMA-IR, TyG, and TyG-BMI index-with HF risk.
methodsData from 7,668 participants in the NHANES 2011-2016 survey were analyzed. Multivariable logistic regression was used to assess the relationship between HOMA-IR, TyG, and TyG-BMI with HF incidence, adjusting for potential confounders. Receiver operating characteristic (ROC) curves, decision curve analysis (DCA), and restricted cubic spline (RCS) analysis were conducted to compare the predictive performance of the three markers.
resultsHOMA-IR (OR = 1.017, 95% CI: 1.006-1.027, P < 0.01), TyG (OR = 1.798, 95% CI: 1.453-2.225, P < 0.001), and TyG-BMI (OR = 1.006, 95% CI: 1.004-1.008, P < 0.001) were all significantly associated with HF risk, with TyG showing the strongest association. ROC curve analysis demonstrated that TyG (AUC = 0.61) and TyG-BMI (AUC = 0.62) had better predictive abilities than HOMA-IR (AUC = 0.6). In subgroup analyses, HOMA-IR showed higher sensitivity in the female population, while TyG-BMI provided a complementary role to TyG in individuals with diabetes.
conclusionTyG showed a stronger association with HF risk than HOMA-IR and TyG-BMI and outperformed HOMA-IR in predicting HF risk, particularly in specific subpopulations. These findings highlight the importance of further research into the clinical application of TyG for early identification and management of HF risk.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.